StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Prevymis (letermovir by Quarter

Prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Prevymis (letermovir: $295M in Q2 2026, up 29.4% from a year earlier. That is the highest of the 30 quarters on record here.

Latest, Q2 2026
295
Period ended Jun 30, 2026
Change on a year earlier
+29.4%
228 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
7
Documents cited below

Where the Q2 2026 figure comes from

“|| Prevymis | 295 | 228 | 29 | 147 | 115 | 28 | 148 | 113 | 31”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026295+29.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026272+30.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025275+27.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025266+27.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025228+21.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025208+19.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024215+22.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024208+32.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 2024188+31.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 2024174+34.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 2023175+48.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 2023157+37.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 2023143+38.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 2023129+37.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 2022118+18.0%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 2022114+18.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up prevymis (letermovir

Cite this data

StockData. (2026). Merck Prevymis (letermovir ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-prevymis

See every metric in the Merck KPI table. Data updated Oct 26, 2026.